Sodium-glucose co-transporter-2 inhibitors suppress atrial natriuretic peptide secretion in patients with newly diagnosed Type 2 diabetes

What Was Tested

This randomized controlled trial paper looks at ANP (Atrial Natriuretic Peptide).

To observe changes in atrial natriuretic peptide levels after treatment with sodium-glucose co-transporter-2 inhibitors in patients with newly diagnosed type 2 diabetes.

Who Took Part

According to the abstract, 2 patients were involved.

PubMed indexes the participants as middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized and placebo-controlled.

The patients were allocated by chance, so the ANP (Atrial Natriuretic Peptide) group and the comparison group should start out alike.

A placebo (an inactive look-alike) gave the ANP (Atrial Natriuretic Peptide) group a baseline to be compared against.

The researchers analysed atrial natriuretic peptide concentrations, using an enzyme-linked immunosorbent assay.

In addition, sodium and HbA1c levels were measured at baseline, 12 weeks and 24 weeks and blood lipid levels and insulin sensitivities at baseline and 24 weeks.

What Was Measured

PubMed files the paper under topics including Atrial Natriuretic Factor, Benzhydryl Compounds, Blood Glucose, Cholesterol, LDL, Diabetes Mellitus, Type 2, Enzyme-Linked Immunosorbent Assay and Glucosides.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of ANP (Atrial Natriuretic Peptide) in 2 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2016 (Diabetic medicine : a journal of the British Diabetic Association), a journal based in England.

More context: the ANP (Atrial Natriuretic Peptide) compound page, all human trials.